A Phase 3 interventional study of Rifaximin and Xifaxan® in Diarrhea, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-05.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.
Among the 19 studies testing rifaximin in Diarrhea, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 10 in phase 3, and was the 13th registered.
879 studies on the registry are indexed under Diarrhea; 77 are open to participants now.
Browse Diarrhea studies →1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2016.
This study's enrollment of 739 is above the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 210 across the 19 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actavis Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 1 study filed under Diarrhea — fewer than ten, so there is no comparison to draw.
1 of the studies testing rifaximin in Diarrhea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing rifaximin in Diarrhea, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in participants with travelers' diarrhea.
This is a randomized, placebo-controlled bioequivalent study with a clinical endpoint in the treatment of travelers' diarrhea. After 3 unformed stools are recorded within the 24 hours immediately preceding randomization, participants are to be randomized to receive the generic rifaximin 200 mg oral tablet, Xifaxan (the reference listed drug)200 mg oral tablet, or placebo 3 times daily for 3 days (that is; on Days 1, 2, and 3).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 1 of the following signs and symptoms of enteric infection:
Exclusion Criteria:
Presence of:
Administration of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
Drug: Rifaximin
Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
Drug: Xifaxan®
Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
Drug: Placebo Tablet
Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population
Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Bioequivalence evaluation between test (generic rifaximin 200 mg tablets) and reference groups (xifaxan 200 mg tablets) was conducted in this endpoint, hence placebo group was not included. Participants who were discontinued early from the study due to lack of treatment effect after completing 9 doses within 72 hours from the time of first dose were included in the PP population using Last Observation Carried Forward (LOCF) method. Additionally, participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea were discontinued and included in the PP population analysis using LOCF.
Time frame: TOC visit (Day 5, 6 or 7)
Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population
Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Participants discontinued early for reasons other than "lack of treatment effect after completing 9 doses within 72 hours from the time of first dose" and for "participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea" were included in the mITT population analysis using LOCF.
Time frame: TOC visit (Day 5, 6 ,or 7)
Time to Last Unformed Stool (TLUS)
TLUS was defined as the interval beginning with the first dose of study drug and ending with the last unformed stool passed within a period of 120 hours (within 48 hours from the time of last dose \[at 72 hours\]). Mathematically, TLUS was calculated as follows. TLUS (hours) = date/time of last unformed stool within 48 hours from the time of last dose - date/time of first dose.
Time frame: Day 1 to Day 5
Percentage of Participants Who Achieved Microbiological Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose)
Participants were considered to have achieved microbiological cure if the pathogen identified at Day 1 is no longer found in the stool at the TOC visit.
Time frame: TOC visit (Day 5, 6, or 7)
| Milestone | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets |
|---|---|---|---|
| Started | 247 | 248 | 244 |
| Safety population | 246 | 247 | 244 |
| Modified intent-to-treat population | 183 | 186 | 180 |
| Per-protocol analysis set | 182 | 181 | 176 |
| Completed | 245 | 246 | 238 |
| Not completed | 2 | 2 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Participant taken prohibited medication | 0 | 1 | 1 |
Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Bioequivalence evaluation between test (generic rifaximin 200 mg tablets) and reference groups (xifaxan 200 mg tablets) was conducted in this endpoint, hence placebo group was not included. Participants who were discontinued early from the study due to lack of treatment effect after completing 9 doses within 72 hours from the time of first dose were included in the PP population using Last Observation Carried Forward (LOCF) method. Additionally, participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea were discontinued and included in the PP population analysis using LOCF.
| Participants | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets |
|---|---|---|
| Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population | 90 | 93 |
TLUS was defined as the interval beginning with the first dose of study drug and ending with the last unformed stool passed within a period of 120 hours (within 48 hours from the time of last dose \[at 72 hours\]). Mathematically, TLUS was calculated as follows. TLUS (hours) = date/time of last unformed stool within 48 hours from the time of last dose - date/time of first dose.
| hours | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets |
|---|---|---|---|
| Time to Last Unformed Stool (TLUS) | 65.25 (3.93 to 119.42) | 65.75 (14.10 to 117.08) | 67.01 (16.65 to 117.87) |
Participants were considered to have achieved microbiological cure if the pathogen identified at Day 1 is no longer found in the stool at the TOC visit.
| percentage of participants | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets |
|---|---|---|---|
| Escherichia coli | 25.5 | 31.9 | 17.4 |
| Enterotoxigenic Escherichia coli (ETEC) | 43.5 | 54.5 | 68.4 |
| Enteroaggregative Escherichia coli (EAEC) | 32.0 | 27.3 | 26.1 |
| Other microorganisms | 70.6 | 81.8 | 92.9 |
| Stool microscopy for ova and parasites | 83.3 | 100.0 | 100.0 |
Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Participants discontinued early for reasons other than "lack of treatment effect after completing 9 doses within 72 hours from the time of first dose" and for "participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea" were included in the mITT population analysis using LOCF.
| Participants | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets |
|---|---|---|---|
| Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population | 91 | 95 | 86 |
Collected over Day 1 up to Day 7. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Generic Rifaximin 200 mg Tablets | 0/246 (0%) | 0/246 (0%) | 17/246 (6.9%) |
| Xifaxan 200 mg Tablets | 0/247 (0%) | 0/247 (0%) | 17/247 (6.9%) |
| Rifaximin Placebo Tablets | 0/244 (0%) | 0/244 (0%) | 24/244 (9.8%) |
| Event | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets |
|---|---|---|---|
| Rectal tenesmusGastrointestinal disorders | 3/246 | 4/247 | 8/244 |
| FlatulenceGastrointestinal disorders | 4/246 | 3/247 | 4/244 |
| Abdominal painGastrointestinal disorders | 3/246 | 0/247 | 3/244 |
| NauseaGastrointestinal disorders | 0/246 | 3/247 | 3/244 |
| HeadacheNervous system disorders | 2/246 | 2/247 | 3/244 |
| Defecation urgencyGastrointestinal disorders | 1/246 | 1/247 | 2/244 |
| LymphocytosisBlood and lymphatic system disorders | 0/246 | 0/247 | 1/244 |
| Alanine aminotransferase increasedInvestigations | 0/246 | 0/247 | 1/244 |
| NeutropeniaBlood and lymphatic system disorders | 0/246 | 0/247 | 1/244 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/246 | 0/247 | 1/244 |
Randomized population included all the participants who satisfied the inclusion and exclusion criteria and were randomized into the study.
| Age, Continuous(years) | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets | Total |
|---|---|---|---|---|
| Mean | 42.5 ± 15.78 | 44.3 ± 16.58 | 42.0 ± 15.21 | 42.9 ± 15.87 |
| Sex: Female, Male(Participants) | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets | Total |
|---|---|---|---|---|
| Female | 123 | 130 | 132 | 385 |
| Male | 124 | 118 | 112 | 354 |
| Ethnicity (NIH/OMB)(Participants) | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets | Total |
|---|---|---|---|---|
| Hispanic or Latino | 189 | 188 | 188 | 565 |
| Not Hispanic or Latino | 58 | 58 | 54 | 170 |
| Unknown or Not Reported | 0 | 2 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Generic Rifaximin 200 mg Tablets | Xifaxan 200 mg Tablets | Rifaximin Placebo Tablets | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 2 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 23 | 18 | 13 | 54 |
| White | 208 | 222 | 220 | 650 |
| More than one race | 13 | 5 | 9 | 27 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2016 to primary completion in Feb 2017, 13 months.
Results were first posted in Dec 2019, 2 years 9 months after primary completion.
Of 30 phase 3 interventional studies under Diarrhea, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 38. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin